Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NATIVE
  • Sponsors Inventiva Pharma

    • Most Recent Events

    • 14 Nov 2023 Results assessing the correlation between ADP increase and lanifibranor for histological features of NASH severity, and biomarkers of active NASH and fibrosis, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 26 Jun 2023 Results evaluating ADP at BL, ADP fold-change at EOT, and correlation between ADP change and response of markers, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 24 Jun 2023 Results assessing correlation betweensteatosis and CMH markers at baseline (BL) and between steatosisreduction with lanifibranor and improvement of CMH markers presented at the European Association for the Study of the Liver Congress 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top